RECURSION PHARMACEUTICALS, INC. (RXRX) — SEC Financial Statements & Analysis

RECURSION PHARMACEUTICALS, INC. (RXRX) is a biological products, (no diagnostic substances) company, incorporated in DE. RECURSION PHARMACEUTICALS, INC. trades on Nasdaq as: RXRX. RECURSION PHARMACEUTICALS, INC. (RXRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, RECURSION PHARMACEUTICALS, INC. carries a market cap of $1.95B, a P/E ratio of -3.77x, a P/B ratio of 2.14x, a P/S ratio of 35.62x, an enterprise value of $1.41B, and an EV/EBITDA multiple of -3.03x. On profitability, it posts a gross margin of 3.48%, an operating margin of -991.72%, a net margin of -945.92%, a Return on Equity (ROE) of -56.58%, a Return on Assets (ROA) of -41.26%, and a Return on Invested Capital (ROIC) of -138.95%. Per share, it reports EPS of $-0.97, diluted EPS of $-0.97, free cash flow per share of $-0.66, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -15.08% year-over-year, net income growth of -20.06% year-over-year, and EPS growth of -37.34% year-over-year. On the balance sheet, it maintains a current ratio of 5.03x, a quick ratio of 4.96x, working capital of $483.58M, a debt-to-equity ratio of 0.33x, a debt ratio of 0.25, free cash flow of $-352.27M (TTM), and net debt of $-542.62M. Figures sourced from SEC EDGAR.

Market Cap

$1.95B

P/E TTM

-3.77x

EPS TTM

$-0.97

P/B TTM

2.14x

ROE TTM

-56.58%

ROA TTM

-41.26%

Debt To Equity

0.33x

Free Cash Flow TTM

$-352.27M

Net Revenue TTM Growth 1Y

-15.08%

Data as of 2026-06-30 · Source: SEC EDGAR